EMA advises clinical trial managers over impact of war in Ukraine

Clinical trials in the Ukraine could be impacted by Russia’s invasion of the country, which is why the EMA is now offering advice on how to proceed based on lessons learned during Covid-19.

Employees at a Ukrainian hospital in Trostyanets say Russian forces have attacked the hospital during its siege of the city | Photo: Thomas Peter/REUTERS / X90176

Russia’s invasion of Ukraine has been the cause of many disruptions in the region at large, and there is now also a great chance of clinical trials being impacted, according to the European Medicines Agency (EMA).

The EMA is therefore offering to consult with companies on how to manage the impacts on clinical trials from the war. Alongside the European Commission and the Heads of Medicines Agencies (HMA), the EMA’s initiative offers advice to companies for how they can find flexible approaches through the crisis.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs